Latest Breaking News On - Antidepressant properties - Page 1 : comparemela.com

Diamond Therapeutics to present groundbreaking study at NIH event News provided by Share this article Share this article Dr. Edward Sellers, head of Diamond s clinical advisory board, will speak about the benefits of low-dose psilocybin TORONTO, May 27, 2021 /PRNewswire/ - Diamond Therapeutics Inc. ( Diamond ), a leading psychedelic drug development company focused on sub-perceptual therapies for mental health, is pleased to announce that the head of its clinical advisory board, Dr. Edward Sellers, will be presenting at the NIH s Psilocybin Research Speaker Series on June 4, 2021. Dr. Sellers, who is Professor Emeritus, Pharmacology and Toxicology, Medicine and Psychiatry at the University of Toronto, will be speaking from 12:30 to 1:00 EST.

University of torontoDiamond therapeutics incPsilocybin research speaker seriesEvidence for antidepressant propertiesPsilocybin research speaker series onEdward sellersDiamond therapeuticsResearch speaker seriesProfessor emeritusPsilocybin enhance motivationPoor performing ratsAntidepressant propertiesLow dosesKetamine enhance motivationபல்கலைக்கழகம் ஆஃப் டொராண்டோவைரம் சிகிச்சை இன்க்